Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -2 | -2 | |||||
| Net profit | $m | 2 | 1 | 1 | -0 | 2 | 4 | 4 |
| EPS reported | $ | 0.08 | 0.08 | |||||
| Operating cashflow per share | $ | 0.03 | 0.04 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | 0.02 | 0.04 | |||||
| Free cash flow | $m | 1 | 2 | |||||
| Net debt | $m | -15 | -18 | |||||
| Book value equity | $m | 16 | 18 | |||||
| Book value per share | $ | 0.33 | 0.37 | |||||
| Number of shares | m | 48.58 | 48.58 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 32.64 | 21.58 | |||||
| P/B LTM | x | 7.14 | 4.61 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | 126.36 | 48.65 | |||||
| EV/EBITDA LTM | x | -46.98 | 48.21 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | 3.06% | 4.63% | |||||
| FCF Yield | % | 0.79% | 2.06% | |||||
| Quality | ||||||||
| ROE | % | 23.09% | 23.88% | |||||
| ROIC | % | -13.45% | -10.10% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +136.81% | +66.80% | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | +123.70% | +61.64% | |||||
| FCF Growth | % | -59.00% | -35.59% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 4.67 | 6.93 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -12.78% | -21.31% | |||||
| Net debt/Equity | x | -0.91 | -0.98 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Xtra-Gold Resources Corp. is dedicated to identifying and developing gold deposits across Ghana, West Africa. The company's extensive land holdings for mining span 225.87 square kilometers, which include several key ventures: the Kibi project (33.65 sq km), the Banso project (51.67 sq km), the Muoso project (55.28 sq km), the Kwabeng project (44.76 sq km), and the Pameng project (40.51 sq km). Founded in 1998, the corporation operated as RetinaPharma International, Inc. until it adopted its current name, Xtra-Gold Resources Corp., in December 2003. Its main office is located in Nassau, Bahamas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Xtra-Gold Resources Corp. (XTGRF)
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Xtra-Gold Resources Corp. is dedicated to identifying and developing gold deposits across Ghana, West Africa. The company's extensive land holdings for mining span 225.87 square kilometers, which include several key ventures: the Kibi project (33.65 sq km), the Banso project (51.67 sq km), the Muoso project (55.28 sq km), the Kwabeng project (44.76 sq km), and the Pameng project (40.51 sq km). Founded in 1998, the corporation operated as RetinaPharma International, Inc. until it adopted its current name, Xtra-Gold Resources Corp., in December 2003. Its main office is located in Nassau, Bahamas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free